Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The Florida State University Research Foundation is currently handling 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, HIRAKIS, SOPHIA P, who is also the busiest examiner for the company. The prosecution is concentrated within 1 distinct art unit, meaning all current activity is localized to a single technical group. With 1 pending office action and 1 distinct examiner, the company's active portfolio is entirely under the review of HIRAKIS, SOPHIA P.
The busiest examiner pending count of 1 matches the total pending office actions, indicating that no other examiners are currently reviewing the company's applications. Practitioners should focus on the specific practices of this 1 distinct examiner within the 1 distinct art unit, as there is no diversification of examiner perspectives in the current workload. The success of the company's current prosecution efforts depends on the resolution of this 1 pending office action. This 1 distinct examiner represents the company's only active engagement with the office in the Biotechnology & Pharmaceuticals area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HIRAKIS, SOPHIA P | 1 | 57.4% | +69.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18253031 | Small Molecule Inhibitors of SARS-CoV-2 Infections | HIRAKIS, SOPHIA P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18253031 | Small Molecule Inhibitors of SARS-CoV-2 Infections | HIRAKIS, SOPHIA P | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18253031 | Small Molecule Inhibitors of SARS-CoV-2 Infections | HIRAKIS, SOPHIA P | 1623 | §102§103§112 | Non-Final OA | — | Pending | May 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Florida State University Research Foundation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sophia P Hirakis has the most, with 1 of The Florida State University Research Foundation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.